20 May 2013
Keywords: bioMerieux, Biocartis, Molecular diagnostics, Equity stake
Article | 09 November 2010
French firm bioMerieux (Euronext: BIM) and privately-held Biocartis of Switzerland have entered into a strategic agreement to co-develop assays on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 November 2010
8 November 2010
17 May 2013
© 2013 thepharmaletter.com